Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection

Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection
复制标题

DOI:
10.1161/01.cir.0000124480.32233.8a
复制
发表时间:
2004-04-06
期刊:
影响因子:
37.8
通讯作者:
Waters, DD
Waters, DD
中科院分区:
医学1区
文献类型:
--
作者:
Hsue, PY;Lo, JC;Waters, DD

文献摘要

被引文献

相似文献

背景--HIV感染患者发生冠状动脉事件的风险可能增加。本研究的目的是确定预测指标的颈动脉内膜中层厚度(IMT)在艾滋病患者在基线和测量IMT进展超过1 year.Methods和结果-我们测量血脂,炎症标志物,和IMT在148艾滋病病毒感染的成年人(平均年龄,45 +/- 8岁)和63年龄和性别匹配的艾滋病病毒未感染的对照组。HIV感染的平均持续时间为11年,蛋白酶抑制剂治疗的中位持续时间为3.3年。HIV患者的平均基线IMT为0.91 ± 0.33 mm,对照组为0.74 ± 0.17 mm(P = 0.0001)。HIV患者基线IMT的多变量预测因子为年龄(P < 0.001)、LDL胆固醇(P < 0.001)、香烟包年(P = 0.005)、拉丁裔(P = 0.062)和高血压(P = 0.074)。当对照组加入到分析中时,HIV感染是IMT的独立预测因子(P = 0.001)。121名HIV患者在1年时重复IMT测量的进展率为0.074 +/- 0.13 mm,而27名对照受试者为-0.006 +/- 0.05 mm(P = 0.002)。年龄(P < 0.001)、拉丁裔(P = 0.02)和最低CD 4计数
Background - HIV-infected patients may be at increased risk for coronary events. The purpose of this study was to identify predictors of carotid intima-media thickness (IMT) in HIV patients at baseline and to measure IMT progression over 1 year.Methods and Results - We measured blood lipids, inflammatory markers, and IMT in 148 HIV-infected adults ( mean age, 45 +/- 8 years) and in 63 age- and sex-matched HIV-uninfected control subjects. The mean duration of HIV infection was 11 years, and the median duration of protease inhibitor treatment was 3.3 years. Mean baseline IMT was 0.91 +/- 0.33 mm in HIV patients and 0.74 +/- 0.17 mm in control subjects (P = 0.0001). Multivariable predictors of baseline IMT in HIV patients were age ( P < 0.001), LDL cholesterol (P < 0.001), cigarette pack-years (P = 0.005), Latino race (P = 0.062), and hypertension (P = 0.074). When the control group was added to the analysis, HIV infection was an independent predictor of IMT (P = 0.001). The rate of progression among the 121 HIV patients with a repeated IMT measurement at 1 year was 0.074 +/- 0.13 mm, compared with -0.006 +/- 0.05 mm in 27 control subjects (P = 0.002). Age (P < 0.001), Latino race (P = 0.02), and nadir CD4 count